ABCL

In the past six months, AbCellera reported its Q3 2025 financial results and appointed Dr. Stephen Quake to its Board of Directors. The company announced a settlement and patent license agreement with Bruker Corporation, which significantly contributed to its Q4 2025 revenue. The first patients were dosed in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. AbCellera reported its full-year 2025 business results, beating EPS estimates for Q4 2025, but remained unprofitable. Several firms initiated or reiterated coverage, with positive ratings and target prices. Baker Bros. Advisors increased its stake in AbCellera to 10.8% of outstanding shares. ABCL shares increased by 53.2% since the beginning of the year, with an 18% gain in the week leading up to May 9, 2026. However, individual investors experienced a 10% stock drop in February 2026. AbCellera is scheduled to report its Q1 2026 financial results on May 11, 2026.